Vircell Launches New Independent Molecular Control to Combat Monkeypox Outbreak
By LabMedica International staff writers Posted on 31 Jul 2022 |
Despite the fact that the first human cases of monkeypox were reported in 1970 in several African countries, it has not been until May 2022 when multiple cases of monkeypox were identified in different non-endemic countries, causing the current outbreak. By the time that the WHO (World Health Organization) declared the Moneypox a public health emergency of international concern in July 2022, Vircell (Granada, Spain) had already developed several solutions in order to help laboratories to detect this new menace. Vircell has now launched a new independent molecular control, Amplirun Monkeypox Virus DNA Control, which will help laboratories all over the world to combat the current outbreak.
Vircell is a leading provider of independent external run controls for nucleic acid testing with a long-term career in infectious disease diagnostics. During the COVID-19 pandemic, the company had developed SARS-COV-2 detection kits in record time, and it has now once again demonstrated its ability to adapt to changing laboratory needs with the newest solutions. Among Vircell’s solutions to detect monkeypox, the Amplirun Monkeypox Virus DNA Control stands out as a positive amplification control which contains purified DNA of Monkeypox virus to be used as a control research technique based on nucleic acids amplification. Some of the product’s outstanding features are:
- Complete genome DNA control.
- Any target can be amplified.
- Allows validation of RTPCR assays.
- Precise concentration in copies/µl.
- Non-infectious materials with inactivation certificate.
- Lyophilized presentation ensures stability and reduces transport costs. No special transportation conditions are required.
- Independent third-party controls valid for any molecular testing platform
Amplirun Monkeypox Virus DNA Control could be used as:
- Quality assurance of the amplification testing.
- Limit of detection and assay specificity.
- Lot-to-lot verification assay.
- Development, optimization and validation of new assays.
- Training and trial purposes.
- Regulatory requirements and accreditation compliance.
Related Links:
Vircell
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders